Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Transplantation. 2020 Mar;104(3):526-534. doi: 10.1097/TP.0000000000002876.
The rs58542926 polymorphism in transmembrane 6 superfamily member 2 (TM6SF2) is a genetic factor predisposing to nonalcoholic fatty liver disease. We aimed to explore the effect of recipient and donor TM6SF2 rs58542926 genotypes on liver graft fat content after liver transplantation.
Steatosis was evaluated in liver biopsies from 268 adult recipients. The influence of recipient and donor TM6SF2 genotypes, patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 genotypes, and nongenetic factors on the steatosis grade assessed 6-30 months after transplantation was analyzed by ordinal logistic regression.
The presence of the TM6SF2 c.499A allele in the donor (P = 0.014), PNPLA3 c.444G allele in the donor (P < 0.001), posttransplant body mass index (P < 0.001), and serum triglycerides (P = 0.047) independently predicted increased liver fat content on multivariable analysis, whereas noncirrhotic liver disease, as an indication for liver transplantation, was associated with lower risk of steatosis (P = 0.003). The effects of the donor TM6SF2 A and PNPLA3 G alleles were additive, with an odds ratio of 4.90 (95% confidence interval, 2.01-13.00; P < 0.001), when both minor alleles were present compared with an odds ratio of 2.22 (95% confidence interval, 1.42-3.61; P = 0.002) when only one of these alleles was present.
The donor TM6SF2 c.499A allele is an independent risk factor of liver graft steatosis after liver transplantation that is additive to the effects of donor PNPLA3 c.444G allele.
跨膜 6 超家族成员 2(TM6SF2)的 rs58542926 多态性是导致非酒精性脂肪性肝病的遗传因素。本研究旨在探讨受体和供体 TM6SF2 rs58542926 基因型对肝移植后肝移植物脂肪含量的影响。
对 268 例成年受体的肝活检标本进行脂肪变性评估。通过有序逻辑回归分析受体和供体 TM6SF2 基因型、载脂蛋白 C3 基因(APOC3)rs765409 基因型、非遗传因素对移植后 6-30 个月评估的脂肪变性程度的影响。
供体 TM6SF2 c.499A 等位基因(P = 0.014)、供体 PNPLA3 c.444G 等位基因(P < 0.001)、移植后体质量指数(P < 0.001)和血清甘油三酯(P = 0.047)的存在独立预测多变量分析中肝脂肪含量增加,而非肝硬化肝病作为肝移植的适应证与脂肪变性风险降低相关(P = 0.003)。供体 TM6SF2 A 和 PNPLA3 G 等位基因的作用是累加的,当两个次要等位基因都存在时,比值比为 4.90(95%置信区间,2.01-13.00;P < 0.001),而当只有一个等位基因存在时,比值比为 2.22(95%置信区间,1.42-3.61;P = 0.002)。
供体 TM6SF2 c.499A 等位基因是肝移植后肝移植物脂肪变性的独立危险因素,与供体 PNPLA3 c.444G 等位基因的作用相加。